---
title: Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide,
  and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly
  Diagnosed Multiple Myeloma
date: '2023-11-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37936633/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231108170854&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: In summary, Dara-VTD, possibly due to both anti-CD38 antibody
  and thalidomide exposure, imposes a limitation on PBSC collection which can be only
  partly overcome by utilization of ...'
disable_comments: true
---
CONCLUSION: In summary, Dara-VTD, possibly due to both anti-CD38 antibody and thalidomide exposure, imposes a limitation on PBSC collection which can be only partly overcome by utilization of ...